Incanthera PLC - Notice of AGM and Posting of Annual Report
RNS Number : 7148Q
Incanthera PLC
23 June 2020



                                                                          Incanthera plc                                               23 June 2020


("Incanthera" or the "Company")


Notice of Annual General Meeting 2020 and Posting of Annual Report and Accounts


Incanthera plc (AQSE: INC), the specialist oncology company focused on transforming cancer treatment, confirms that the Annual Report and Accounts for the year ended 31 March 2020, and the Notice of Annual General Meeting ("AGM") has been posted to shareholders today.


These documents are also available, in electronic form, for download on the Company's website:


Incanthera's AGM will be held at 11:00 a.m. on Wednesday, 15 July 2020 at Jubilee Hall, Wellow Road, Ollerton, Newark, NG22 9AP.


Impact of Covid-19

The Covid-19 pandemic will affect the format of our AGM, and our priority is to ensure the health and wellbeing of all stakeholders.


Current government guidance restricts all non-essential travel and public gatherings (the "Government Measures"). We fully support the Government Measures, and in order to reduce the risk of infection and ensure shareholders can comply with the current Government Measures, shareholders must not attend the AGM in person this year. The AGM will focus on the formal business of the meeting only and any Shareholders who do attend will not be admitted.

We recognise that the AGM is valued as an opportunity for shareholders to engage with and hear from the Board and we would like to invite shareholders to actively participate by submitting questions to the Board through our Head of Communications, Suzanne Brocks via email to or by post to the Company's Registrar, as detailed within the full Notice of AGM.

Shareholders are strongly encouraged to exercise their votes by submitting their proxy votes electronically or by post. To ensure their vote counts, shareholders should appoint the Chairman of the AGM (and not another named person) as their proxy. Full details on registering a proxy are available in the Notice of AGM.


We will continue to monitor any changes to government guidance over the coming weeks and will adapt our AGM arrangements accordingly. The Company will communicate any updates to the AGM arrangements via its website Shareholders are advised to check the Company's website for the most up to date position.


The Board would like to take this opportunity to thank shareholders for their support and understanding in these unprecedented times and wish them well as we all navigate the impact of Covid-19.



For further enquiries:


Incanthera plc


Tim McCarthy, Chairman


Simon Ward, Chief Executive Officer


Suzanne Brocks, Head of Communications




+44 (0) 7831 675747



+44 (0) 7747 625506



+44 (0) 7776 234600



Aquis Exchange Corporate Adviser:

Cairn Financial Advisers LLP

Jo Turner/James Lewis

+44 (0) 20 7213 0880




Stanford Capital Partners Ltd

Patrick Claridge/John Howes/Bob Pountney

+44 (0) 20 3815 8880




Notes to Editors


Incanthera is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.


The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and the Company is now focussed upon delivering Sol to a commercial partner.


The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions.


Incanthera's strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.


For more information on the Company please visit:






This information is provided by RNS, the news service of the . RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit